Delandistrogene moxeparvovec is under clinical development by Sarepta Therapeutics and currently in the Pre-Registration in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Delandistrogene moxeparvovec’s likelihood of approval (LoA) and phase transition for Duchenne Muscular Dystrophy took place on 30 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Delandistrogene moxeparvovec Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Delandistrogene moxeparvovec overview

SRP-9001 is under development for the treatment of Duchenne muscular dystrophy. It is administered through intramuscular and intravenous routes. The therapy constitutes micro dystrophin gene carried through recombinant adeno-associated virus vector serotype 74  (AAV74).

Sarepta Therapeutics overview

Sarepta Therapeutics (Sarepta) discovers and develops unique RNA-targeted medicines to treat rare diseases. The company develops its pipeline products using its multi-platform Precision Genetic Medicine Engine in gene therapy, RNA, and gene editing. The company’s platform is based on its pioneering work with phosphorodiamidate morpholino oligomer (PMO) chemistries. Its commercial products include Exondys 51, Vyondys 53 and Amondys 45 indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene. Its pipeline product includes SRP-5051, SRP-9001, SRP-9003 and SRP-5045 indicated for the treatment of DMD, limb-girdle muscular dystrophies (LGDMs) and other neuromuscular and central nervous system disorders. Sarepta is headquartered in Cambridge, Massachusetts, the US.

Quick View Delandistrogene moxeparvovec LOA Data

Report Segments
  • Innovator
Drug Name
  • Delandistrogene moxeparvovec
Administration Pathway
  • Intramuscular
  • Intravenous
Therapeutic Areas
  • Genetic Disorders
Key Developers
Highest Development Stage
  • Pre-Registration

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.